BioNTech SE - ADR vs KraneShares CSI China Internet ETF — how do they compare? BioNTech SE - ADR trades at $89.96 (market cap $22.86B), while KraneShares CSI China Internet ETF trades at $27.23. Which is the better fit depends on your goals.
| BNTX | KWEB | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | Sector/Thematic |
52-Week High | $119.34 | $42.94 |
52-Week Low | $83.89 | $23.63 |
Enterprise Value | $6.53B | — |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
KWEB trades at $26.23, down 0.57% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF provides exposure to Chinese internet and AI companies, benefiting from government support and AI-driven growth, though key financial ratios are unavailable. Recent news highlights China's push for tech self-reliance and strong export performance.
Outlook is mixed: AI expansion and attractive valuations offer upside, but geopolitical tensions and regulatory risks pose challenges. The stock's performance hinges on China's economic policies and global tech competition, requiring careful risk assessment for investors.
Trailing returns across standard periods
Latest headlines on both assets
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →